Clad-LABU conditioning before allogeneic stem cell transplant for relapsed or refractory AML/MDS in older adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm study testing a Clad-LABU conditioning regimen given before allogeneic hematopoietic stem cell transplantation in elderly patients with relapsed or refractory AML or MDS. Eligible participants are adults aged 50 years or older who meet relapsed or refractory disease criteria and are candidates for allo-HSCT. The study will collect data on transplant outcomes, factors linked to efficacy, and treatment-related adverse events following the conditioning and transplant. All treatment and follow-up are performed at The First Affiliated Hospital of Soochow University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 50years.
* Meet the 2022 World Health Organization (WHO) diagnostic criteria for acute myeloid leukemia (AML),MDS, and be diagnosed with relapsed/refractory AML after treatment, fulfilling any of the following definitions:
* Relapsed AML: Reappearance of leukemic cells in peripheral blood, bone marrow blasts \>5% (excluding other causes such as bone marrow regeneration after consolidation chemotherapy), or extramedullary infiltration of leukemic cells after achieving complete remission (CR or CRi).
* Refractory AML: Newly diagnosed cases that failed to respond after 2 courses of standard therapy; patients who relapsed within 12 months after consolidation therapy following CR; patients who relapsed after 12 months but failed to respond to conventional chemotherapy; patients with 2 or more relapses; persistent extramedullary leukemia.
* MDS:Myelodysplastic Neoplasms (MDS)MDS are a group of clonal hematopoietic stem cell disorders characterized by: Dysplastic hematopoiesis (abnormal development of blood cells in the bone marrow); Cytopenias (one or more lineages of blood cells are reduced in number); Increased risk of transformation to acute myeloid leukemia (AML).Key diagnostic criteria (per WHO 2022 classification): Persistent cytopenia(s) for ≥4 months (unless specific genetic abnormalities are present); Morphological dysplasia in ≥10% of cells in one or more lineages; Presence of MDS-defining genetic abnormalities (e.g., SF3B1 mutation, isolated del(5q), TP53 biallelic alteration).
* Cardiac, hepatic, and renal function test results within the following limits:

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN);Total bilirubin ≤ 3 × ULN;Serum creatinine ≤ 2 × ULN or creatinine clearance ≥ 40 mL/min;Left ventricular ejection fraction (LVEF) measured by echocardiography or multigated acquisition (MUGA) scan within the normal range (\>50%).

* Have a suitable allogeneic donor.
* Expected survival ≥ 1 month.
* Karnofsky Performance Status (KPS) ≥ 60%, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
* The patient understands the study protocol and voluntarily signs the informed consent form.

Exclusion Criteria:

* Patients had serious adverse reactions to investigational drugs such as allergies;
* Patients with a history of immunodeficiency, or other acquired or congenital diseases, immunodeficiency diseases, and a history of organ transplantation;
* Patients with hypertension, ventricular arrhythmia requiring clinical intervention, acute coronary syndrome, congestive heart failure, stroke, or other grade III or higher cardiovascular events within 6 months;
* Patients received Class II or higher surgery within 4 weeks prior to enrollment;
* Patient has an active and difficult-to-control infection, including but not limited to active fungal, bacterial, or viral infections that require systemic treatment, such as active HIV, hepatitis B or C;
* Patient has active central nervous system leukemia infiltration;
* Pregnant or lactating patients;
* Patient is currently participating in another clinical studies;
* Other conditions where the investigator deems the patient unsuitable for inclusion.

Where it's running

• The First Affiliated Hospital of Soochow University
  Suzhou, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Xiaojin Wu
• Email: wuxiaojin@suda.edu.cn
• Phone: +8613057493105

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Ivosidenib as maintenance therapy for IDH1-mutated AML or high-risk MDS in patients ineligible for transplant

  This study tests whether continuing ivosidenib after induction helps people with IDH1-mutated AML or high-risk MDS who can’t have a transplant, to see if it helps keep cancer from returning.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07607418

• Haplo-cord Blood Transplant for AML and high-risk MDS

  This study tests a haploidentical-cord blood stem cell transplant approach in patients with AML or high-risk MDS to see how different engraftment patterns affect outcomes.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian and 3 other locations · NCT07588360

• Wearable monitoring to collect health data in people receiving transfusions for blood cancers

  This project will try a wrist-worn accelerometer to see if continuous activity and symptom tracking helps doctors understand and support adults with MDS, AML or related blood cancers who need transfusions.

  Recruiting University of Oxford · Oxford, OXFORDSHIRE · NCT07511829

• Romiplostim versus daily rhTPO for speeding platelet recovery after donor stem-cell transplant

  This trial will test whether a once-weekly romiplostim injection helps platelets recover faster and safely than daily rhTPO in adults 18–65 with MDS or severe aplastic anemia after a donor stem-cell transplant.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07400341

• CG009301 for adults with relapsed or treatment‑resistant blood cancers

  This trial will try a new drug called CG009301 to see if it's safe and helps adults whose leukemia or related blood cancers have come back or not responded to prior treatment.

  Recruiting at 3 sites Phase 1 Cullgen (Shanghai),Inc · Nanchang and 2 other locations · NCT07347171

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.